New drug testing rule combats Opiod Epidemic

Posted by Tony Brock | Dec 27, 2017 | 0 Comments

Image result for drug testing

 Effective Jan. 1, 2018 four opioids are added to the DOT's drug-testing panel for safety-sensitive positions. Those opioids include hydrocodone, hydromorphone, oxymorphone and oxycodone. In addition, labs must add methylenedioxyamphetamine (MDA) as an initial test analyte and remove methylenedioxyethylamphetamine (MDEA) as a confirmatory test analyte.

That means that DOT-regulated employers will be required to test for these highly abused opioids beginning on January 1, 2018. DOT says approximately 6.3 million DOT-regulated tests occur per year and about one percent of the submitted specimens is expected to be confirmed as positive for the added analytes. That's an anticipated 63,000 positive tests per year nationwide.

The final rule also clarifies certain existing drug-testing program provisions and definitions, makes technical amendments and removes the requirement for employers and third-party administrators to submit blind specimens.

The latest revisions are intended to harmonize with the “Mandatory Guidelines for Federal Workplace Drug Testing Programs” which were revised by the Dept. of Health and Human Services.

About the Author

Tony Brock



There are no comments for this post. Be the first and Add your Comment below.

Leave a Comment


Aenean lacinia bibendum nulla sed consectetur. Donec sed odio dui. Maecenas sed diam eget risus varius blandit sit amet non magna. Nulla vitae elit libero, a pharetra augue. Curabitur blandit tempus porttitor. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Cras justo odio, dapibus ac facilisis in, egestas.

Workers' Compensation For Injured Truckers

Download now

Review Us